Navigation Links
Apollo Medical Holdings Announces Record Fiscal Year-End Results
Date:5/3/2013

GLENDALE, Calif., May 3, 2013 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed") (OTCQB: AMEH), an integrated physician-driven healthcare delivery company that puts 'Patients First,' today announced its fiscal year-end results for the three and twelve months ended January 31, 2013. 

Financial Highlights for Full Fiscal Year 2013 Compared to Full Fiscal Year 2012:

  • Net revenues climbed 52.2% to $7.8 million from $5.1 million due largely to the signing of new hospital contracts during fiscal 2013, coupled with new revenue stemming from the Company's expanded service offerings.
  • Gross profit increased 49.2% to $1.46 million from $978,000.
  • After factoring non-cash stock-based compensation totaling approximately $1.9 million, loss from operations on a GAAP basis rose to $2.1 million from $413,000.
  • Non-GAAP* Adjusted EBITDA increased to approximately $4,200 from a Non-GAAP Adjusted EBITDA loss of approximately $219,000.
  • Financial Highlights for Three Months Ended January 31, 2013 Compared to Three Months Ended January 31, 2012:

  • Net revenues totaled $2.5 million, rising 63.7% from $1.5 million. 
  • Gross profit rose 34.7% to approximately $547,000 from $406,000.
  • Operating loss doubled to $525,000 from $269,000; the increase is attributable primarily to costs associated with the development and expansion of ApolloMed ACO.
  • Non-GAAP* Adjusted EBITDA loss totaled $189,523, rising 12.0% from $169,245.
  • As of January 31, 2013, the Company had $1.18 million in cash and cash equivalents, $1.58 million in accounts receivable and total stockholders' deficit of approximately $391,000.

    Key Operational Highlights for Fiscal Year 2013

  • In March 2012, Care1st Health Plan contracted with ApolloMed Hospitalists to provide inpatient care services to its members at all hospitals in Los Angeles which ApolloMed serves.
  • In July, ApolloMed ACO was officially selected by the Centers for Medicare and Medicaid Services to participate in the Medicare Shared Savings Program as one of only eight ACOs selected in the State of California during the year.
  • In September, ApolloMed Hospitalists was signed by L.A. Care Health Plan, the largest Medi-Cal managed care plan in California and the largest public health plan in the nation, to provide hospitalist management services at all hospitals in Los Angeles which ApolloMed serves.
  • In October, Glendale Memorial Hospital, recognized as one of 'America's 50 Best Hospitals' by Healthgrades, chose ApolloMed to provide critical care services for its Intensive Care Unit.
  • Also in October, the Company expanded its ApolloMed Hospitalists business into Orange County, California, initiating 24/7 coverage at four area hospitals:  Fountain Valley Regional Medical Center, a 400-bed full-service acute care facility owned by Tenet Healthcare Corporation and one of the largest hospitals in the county; Huntington Beach Hospital, a 131-bed facility owned by Prime Healthcare; Kindred Hospital in Westminster, a 99-bed long term acute care (LTAC) facility; and Kindred Hospital in Santa Ana, a 54-bed LTAC facility. Both LTACs are owned by Kindred Healthcare, the largest diversified provider of post-acute care services in the U.S.
  • In late November, ApolloMed Hospitalists signed a service agreement with California Hospital Medical Center to provide hospitalist services to the 316-bed acute care hospital located in downtown Los Angeles.
  • During the year, the Company expanded its Board of Directors with the welcome addition of Gary Augusta, Mark Meyers, Mitchell Creem and Ted Schreck, who was named Chairman.
  • Commenting on the yearend results, ApolloMed CEO Warren Hosseinion, M.D. stated, "On reflection, fiscal 2013 was a very rewarding year for us – a year in which we made vital progress on the expansion of our three core business units; saw material growth in the number of hospitals, physicians and patients we now serve; and gained meaningful traction with our market penetration efforts in Southern and Central California.  Moreover, we are very proud of our many notable accomplishments in the last year that helped us close fiscal 2013 on a $10+ million revenue run rate, which firmly positions us to deliver yet another record year in 2014.  Practicing strict expense discipline and aggressively ramping sales are among are chief priorities in the current fiscal year and are goals that we believe we are well poised to achieve."

    For more details on ApolloMed's fiscal 2013 year-end results, please refer to the Company's 10-K filed with the U.S. Securities Exchange Commission and accessible at www.sec.gov.  

    FINANCIAL CHARTS TO FOLLOW APOLLO MEDICAL HOLDINGS, INC.CONSOLIDATED BALANCE SHEETSJanuary 31,
    2013January 31,
    2012CURRENT ASSETSCash and cash equivalents

    $
    ,176,727

    $
    4,361Accounts receivable, net

    1,582,505

    994,118Advances

    -

    2,140Due from affiliates

    5,648

    5,504Prepaid expenses

    72,628

    45,601Deferred financing costs, current

    34,614

    37,500Total current assets

    2,872,122

    1,249,224Deferred financing costs, non-current

    218,640

    -Property and equipment, net 

    68,142

    43,261Goodwill

    33,200

    32,000Other assets

    30,981

    39,563TOTAL ASSETS$
    3,223,085

    1,364,048LIABILITIES AND STOCKHOLDERS' DEFICITCURRENT LIABILITIES:Accounts payable and accrued liabilities

    $
    950,651

    $
    3,476Notes payable

    594,765

    -Convertible notes payable, net

    -

    596,366Derivative liability

    -

    653,026Stock issuable 

    159,334

    90,000Due to officers

    -

    12,400Total current liabilities

    1,704,750

    1,515,268Convertible notes payable, net

    1,909,714

    150,000Warrant liability

    -

    120,000Total liabilities

    3,614,464

    1,785,268STOCKHOLDERS' DEFICITPreferred stock, par value $0.001 ;

    5,000,000  shares authorized; none issued

    -

    -Common Stock, par value $0.001; 100,000,000 shares authorized,  34,843,441 and 29,335,774 shares issued and outstanding as of January 31, 2013 and 2012, respectively

    34,844

    29,336Prepaid consulting

    (616,014)

    -Additional paid-in-capital

    11,248,566

    1,429,051Accumulated deficit

    (11,022,272)

    (2,117,708)Total

    (354,876)

    (659,321)Non-controlling interest

    (36,503)

    238,101Total stockholders' deficit

    (391,379)

    (421,220)TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT 

    $  3,223,085

    $ 1,364,048 APOLLO MEDICAL HOLDINGS, INC.CONSOLIDATED STATEMENTS OF OPERATIONSYears ended January 31,20132012NET REVENUES

    $
    7,776,131

    $
    5,110,806COST OF SERVICES

    6,316,164

    4,132,399GROSS PROFIT

    1,459,967

    978,407Operating expenses:General and administrative

    3,517,536

    1,379,153Depreciation

    20,918

    12,589Total operating expenses

    3,538,454

    1,391,742LOSS FROM OPERATIONS

    (2,078,487)

    (413,335)Other income (expense)Loss on change in fair value of derivative liabilities

    (5,853,855)

    -Interest expense

    (930,176)

    (304,034)Other (expense) income

    (37,246)

    2,842Total other expenses

    (6,821,277)

    (301,192)LOSS BEFORE INCOME TAXES

    (8,899,764)

    (714,527)Provision for Income Tax

    4,800

    5,819NET LOSS

    $
    (8,904,564)

    $
    (720,346) APOLLO MEDICAL HOLDINGS, INC.CONSOLIDATED STATEMENTS OF OPERATIONSThree Months Ended January 31 ,Year Ended 
    January  31,2013201220132012 

    LOSS FROM OPERATIONS 

    $ (525,083)

    $ (268,754)

    $(2,078,487)

    $(413,335)Depreciation and amortization expense

    6,133

    2,775

    20,918

    12,589EBITDA(518,950)

    (265,979)

    (2,057,569)

    (400,746)Issuance of shares for service

    133,355

    89,400

    1,355,708

    152,400Non-cash stock option expense

    196,072

    7,334

    706,020

    29,333ADJUSTED EBITDA$(189,523)

    $(169,245)

    $4,159

    $(219,013) 

    *Use of Non-GAAP Financial Measures
    In addition to containing results that are determined in accordance with accounting principles generally accepted in the United States of America (GAAP), this press release also contains non-GAAP financial measures. Adjusted EBITDA, as used in this press release, represents Loss from Operations before depreciation, adjusted for issuance of shares for service, stock option expense, amortization of debt discount and impairment of intangibles and losses on discontinued operations. Adjusted EBITDA is a key indicator used by management to evaluate operating performance. While adjusted EBITDA is not intended to replace any presentation included in the consolidated financial statements under GAAP and should not be considered an alternative to operating performance or an alternative to cash flow as a measure of liquidity, the Company believes this measure is useful to investors in assessing the Company's ongoing operating performance and working capital requirements. This calculation may differ in method of calculation from similarly titled measures used by other companies. A reconciliation of adjusted EBITDA to the nearest comparable GAAP financial measure is included in the financial schedules accompanying this press release. The Non-GAAP financial measures, as well as other information in this press release, should be read in conjunction with the Company's financial statements filed with the Securities and Exchange Commission.

    About Apollo Medical Holdings, Inc. (ApolloMed)
    Headquartered in Glendale, California and dedicated to putting the 'Patient First,' ApolloMed is a physician-driven integrated healthcare delivery company, fueled by its commitment to provide exceptional multi-disciplinary care in the communities it serves in Southern and Central California.  ApolloMed is addressing the healthcare needs of the nation's largest population center by leveraging its integrated healthcare delivery platform through its complementary physician groups:  ApolloMed Hospitalists and ApolloMed ACO (Accountable Care Organization).  This platform combines hospitalist medicine, critical care medicine, patient care coordination, case management and transition management that enable healthcare organizations to engage in performance payments for utilization efficiency, quality of care objectives and shared accountability arrangements.
    ApolloMed strives to improve medical outcomes with high quality, cost efficient care.
    For more information, please visit www.apollomed.net.

    Forward Looking Statements
    This press release may contain forward-looking statements, including information about management's view of Apollo Medical Holdings, Inc. ("the Company") future expectations, plans and prospects.  In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements.  Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements.  These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements.  Unknown or unpredictable factors also could have material adverse effects on the Company's future results.  The forward-looking statements included in this press release are made only as of the date hereof.  The Company cannot guarantee future results, levels of activity, performance or achievements.  Accordingly, you should not place undue reliance on these forward-looking statements.  Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Apollo Medical Holdings, Inc.

    For More Information, PLEASE CONTACT:
    Hanover|Elite
    Kathy Addison or Dodi Handy
    407-585-1080 or via email at AMEH@hanoverelite.com


    '/>"/>
    SOURCE Apollo Medical Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
    2. Apollo Telemedicine Service Launched in Yangon
    3. Apollo Hospitals to Establish the First Proton Therapy Center for Cancer Treatment to Serve Over 3.5 Billion People
    4. Apollo Hospitals Perform Revolutionary Minimally Invasive Knee Replacement (Resurfacement) Surgery
    5. Smt. Sheila Dikshit Unveils South Asias First PET SUITE at Indraprastha Apollo Hospitals
    6. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
    7. Medical Device Developers - Network at BIOMEDevice Boston Next Week
    8. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
    9. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
    10. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
    11. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
    (Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
    (Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
    (Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
    (Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
    (Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
    Breaking Medicine News(10 mins):